Yüklüyor......
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the tumorigenesis and progression of this disease as well as in the resistance to radiotherapy (RT). While several anti-EGFR agents ha...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536039/ https://ncbi.nlm.nih.gov/pubmed/31165040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00383 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|